Forbion European Acquisition Corp.

Forbion European Acquisition Corp. (Nasdaq: FRBN) was a healthcare and life sciences-focused SPAC sponsored by Forbion Capital Partners, a Dutch venture capital firm with a long track record in European biopharmaceuticals and biotechnology. The company completed its IPO in 2021, listing on Nasdaq with a mandate to identify and acquire innovation-stage life sciences businesses, with a particular emphasis on the European market. In November 2023, FRBN filed a Form 15-12G with the SEC, formally deregistering its securities — a step typically taken when a blank-check company winds down after its combination window lapses without a completed transaction. Sign up at SpacDesk for the full filing history, sponsor background, and deal-timeline analytics on FRBN and hundreds of other SPAC vehicles.